TC BioPharm Announces Filing Of IND For TCB-008 - Quick Facts

(RTTNews) - TC BioPharm Holdings PLC (TCBP) announced submission of an Investigational New Drug application to the FDA for the use of TCB-008 in the treatment of relapse/refractory Acute Myeloid Leukemia. The company said the FDA will review the application and determine the acceptability of the data before TC BioPharm begins its first clinical trial for TCB-008.

"Filing of the IND for TCB-008 is the next step in the clinical development of TCB-008 and aligns with our strategic refocus announced in second quarter of this year to target our clinical strategy to US trials in the future," said Bryan Kobel, CEO of TC BioPharm.

For More Such Health News, visit rttnews.com.